A study testing whether a new weekly shot from Boehringer Ingelheim, survodutide, can improve fatty liver disease.

Who can join

Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

What you take

survodutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The full study runs about 7.3 years; your own time in it is usually shorter.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosi.

Primary condition: Metabolic Dysfunction Associated Steatohepatitis (MASH). Also studied in: Liver Fibrosis.

Who can join, in detail

Key inclusion criteria

• Male or female participants >=18 years (or who are of legal age in countries where that is greater than 18 years) of age at time of consent
• Diagnosis of MASH (non-alcoholic fatty liver disease (NAFLD)) activity score [NAS] >=4
• Stable body weight defined as less than 5% self-reported change in body weight 3 months prior to the screening or during the period between the historical biopsy and randomisation, if a historical biopsy is used
• Be willing to maintain a stable diet and physical activity levels throughout the entire trial Further apply

Key exclusion criteria

• Any of the following liver laboratory test abnormalities at screening:
• Serum AST and/or alanine aminotransferase (ALT) elevation >=5x upper limit of normal (ULN)
• Platelet count <140 000/mm^3 (<140 GI/L)
• Alkaline phosphatase >2x upper limit of normal (ULN)
• Abnormal synthetic liver function as defined by screening central laboratory evaluation:

Where this study is enrolling

This trial has 165 US sites across 30 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2024-09-17. Expected completion: 2031-12-27. Last updated on ClinicalTrials.gov: 2026-05-28.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact